Immix Biopharma Net Income
| IMMX Stock | USD 6.84 0.11 1.63% |
As of the 12th of February 2026, Immix Biopharma retains the Market Risk Adjusted Performance of 0.8694, downside deviation of 4.35, and Risk Adjusted Performance of 0.1926. Immix Biopharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Immix Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immix Biopharma's valuation are provided below:We have found one hundred twenty available fundamental trends for Immix Biopharma, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immix Biopharma regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 58.8 M in 2026. Enterprise Value is likely to rise to about 43.1 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -19.5 M | -18.6 M | |
| Net Loss | -7.4 M | -7.8 M | |
| Net Loss | -19.5 M | -18.5 M | |
| Net Loss | (0.69) | (0.72) | |
| Net Income Per E B T | 1.15 | 1.10 |
Immix | Net Income | Build AI portfolio with Immix Stock |
The evolution of Net Income for Immix Biopharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Immix Biopharma compares to historical norms and industry peers.
Latest Immix Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Immix Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Immix Biopharma financial statement analysis. It represents the amount of money remaining after all of Immix Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Immix Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (21.61 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Immix Net Income Regression Statistics
| Arithmetic Mean | (6,968,263) | |
| Coefficient Of Variation | (127.99) | |
| Mean Deviation | 7,738,225 | |
| Median | (972,811) | |
| Standard Deviation | 8,918,351 | |
| Sample Variance | 79.5T | |
| Range | 23.4M | |
| R-Value | (0.78) | |
| Mean Square Error | 32.7T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (1,385,118) | |
| Total Sum of Squares | 1272.6T |
Immix Net Income History
Other Fundumenentals of Immix Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Immix Biopharma Net Income component correlations
Immix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immix Biopharma is extremely important. It helps to project a fair market value of Immix Stock properly, considering its historical fundamentals such as Net Income. Since Immix Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immix Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immix Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immix Biopharma. Market participants price Immix higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immix Biopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Immix Biopharma's market price often diverges from its book value, the accounting figure shown on Immix's balance sheet. Smart investors calculate Immix Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Immix Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immix Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immix Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immix Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immix Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immix Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immix Biopharma.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Immix Biopharma on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Immix Biopharma or generate 0.0% return on investment in Immix Biopharma over 90 days. Immix Biopharma is related to or competes with Coya Therapeutics, Whitehawk Therapeutics, Oncolytics Biotech, Zentalis Pharmaceuticals, Surrozen, Atossa Genetics, and Instil Bio. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therape... More
Immix Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immix Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immix Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.35 | |||
| Information Ratio | 0.2151 | |||
| Maximum Drawdown | 28.79 | |||
| Value At Risk | (6.08) | |||
| Potential Upside | 14.88 |
Immix Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immix Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immix Biopharma's standard deviation. In reality, there are many statistical measures that can use Immix Biopharma historical prices to predict the future Immix Biopharma's volatility.| Risk Adjusted Performance | 0.1926 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | 0.6883 | |||
| Sortino Ratio | 0.302 | |||
| Treynor Ratio | 0.8594 |
Immix Biopharma February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1926 | |||
| Market Risk Adjusted Performance | 0.8694 | |||
| Mean Deviation | 4.73 | |||
| Semi Deviation | 3.8 | |||
| Downside Deviation | 4.35 | |||
| Coefficient Of Variation | 430.93 | |||
| Standard Deviation | 6.11 | |||
| Variance | 37.37 | |||
| Information Ratio | 0.2151 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | 0.6883 | |||
| Sortino Ratio | 0.302 | |||
| Treynor Ratio | 0.8594 | |||
| Maximum Drawdown | 28.79 | |||
| Value At Risk | (6.08) | |||
| Potential Upside | 14.88 | |||
| Downside Variance | 18.96 | |||
| Semi Variance | 14.41 | |||
| Expected Short fall | (6.05) | |||
| Skewness | 0.7077 | |||
| Kurtosis | 0.3654 |
Immix Biopharma Backtested Returns
Immix Biopharma appears to be slightly risky, given 3 months investment horizon. Immix Biopharma holds Efficiency (Sharpe) Ratio of 0.17, which attests that the entity had a 0.17 % return per unit of risk over the last 3 months. By evaluating Immix Biopharma's technical indicators, you can evaluate if the expected return of 0.97% is justified by implied risk. Please utilize Immix Biopharma's Market Risk Adjusted Performance of 0.8694, risk adjusted performance of 0.1926, and Downside Deviation of 4.35 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Immix Biopharma holds a performance score of 13. The company retains a Market Volatility (i.e., Beta) of 1.64, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immix Biopharma will likely underperform. Please check Immix Biopharma's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immix Biopharma's current trending patterns will revert.
Auto-correlation | 0.50 |
Modest predictability
Immix Biopharma has modest predictability. Overlapping area represents the amount of predictability between Immix Biopharma time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immix Biopharma price movement. The serial correlation of 0.5 indicates that about 50.0% of current Immix Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.5 | |
| Spearman Rank Test | 0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.43 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Immix Biopharma reported net income of (21.61 Million). This is 106.33% lower than that of the Biotechnology sector and 130.86% lower than that of the Health Care industry. The net income for all United States stocks is 103.79% higher than that of the company.
Immix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immix Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immix Biopharma could also be used in its relative valuation, which is a method of valuing Immix Biopharma by comparing valuation metrics of similar companies.Immix Biopharma is currently under evaluation in net income category among its peers.
Immix Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immix Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immix Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Immix Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Immix Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Immix Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immix Biopharma's value.| Shares | Tritonpoint Wealth Llc | 2025-06-30 | 24.5 K | Virtu Financial Llc | 2025-06-30 | 17.8 K | Sbi Securities Co Ltd | 2025-06-30 | 17.5 K | Commonwealth Equity Services Inc | 2025-06-30 | 16 K | Ubs Group Ag | 2025-06-30 | 14 K | The Colony Group Llc | 2025-06-30 | 11.9 K | Royal Bank Of Canada | 2025-06-30 | 11.2 K | Wells Fargo & Co | 2025-06-30 | 330 | Bank Of America Corp | 2025-06-30 | 139 | Bleichroeder Lp | 2025-06-30 | 850 K | Vanguard Group Inc | 2025-06-30 | 698.5 K |
Immix Fundamentals
| Return On Equity | -1.83 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 342.08 M | ||||
| Shares Outstanding | 52.96 M | ||||
| Shares Owned By Insiders | 22.36 % | ||||
| Shares Owned By Institutions | 8.89 % | ||||
| Number Of Shares Shorted | 2.27 M | ||||
| Price To Book | 43.18 X | ||||
| EBITDA | (22.56 M) | ||||
| Net Income | (21.61 M) | ||||
| Cash And Equivalents | 18.4 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.07 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 19.53 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (14.6 M) | ||||
| Short Ratio | 3.01 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Target Price | 11.07 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.31 | ||||
| Market Capitalization | 356.39 M | ||||
| Total Asset | 22.95 M | ||||
| Retained Earnings | (75.02 M) | ||||
| Working Capital | 11.51 M | ||||
| Net Asset | 22.95 M |
About Immix Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immix Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immix Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immix Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.